foodgrad
lactic
acid
bacteria
lab
safe
consum
centuri
human
ferment
food
thu
good
candid
develop
novel
oral
vector
constitut
attract
altern
attenu
pathogen
mucos
deliveri
strategi
herein
review
summar
research
use
lab
mucos
deliveri
vector
therapeut
protein
dna
vaccin
work
base
model
lab
lactococcu
lacti
develop
effici
genet
tool
includ
express
signal
host
strain
heterolog
express
therapeut
protein
antigen
cytokin
enzym
result
recombin
lactococci
strain
test
success
prophylact
therapeut
effect
differ
anim
model
human
papillomaviru
type
induc
tumor
mice
ii
partial
prevent
bovin
blg
allerg
reaction
mice
iii
regul
bodi
weight
food
consumpt
obes
mice
strikingli
tool
success
transpos
lactobacillu
genu
recent
year
within
laboratori
notabl
antioxid
lactobacillu
casei
strain
construct
test
two
chemicallyinduc
coliti
model
parallel
also
develop
strategi
base
use
l
lacti
deliv
dna
mucos
level
abl
show
l
lacti
abl
modul
host
respons
dna
deliveri
today
consid
consist
data
togeth
obtain
group
demonstr
reinforc
interest
use
lab
particularli
lactococci
lactobacilli
strain
develop
novel
therapeut
protein
mucos
deliveri
vector
test
human
clinic
trial
administr
therapeut
molecul
via
mucos
rout
offer
sever
import
advantag
system
deliveri
reduct
secondari
effect
easi
administr
possibl
modul
system
mucos
immun
respons
moreov
direct
deliveri
appropri
medic
molecul
exert
effect
mucos
surfac
effici
prophylact
therapeut
strategi
mucos
surfac
primari
interact
site
organ
environ
thu
repres
major
portal
entri
pathogen
last
fifteen
year
sever
report
success
immunis
varieti
mucos
vector
vaccin
induc
effici
system
immun
respons
less
collater
side
effect
system
vaccin
addit
mucos
immunis
easili
perform
without
need
needl
syring
therebi
elimin
requir
train
personnel
import
featur
mass
vaccin
program
nevertheless
major
disadvantag
larg
amount
protein
need
administ
due
fact
major
protein
degrad
small
quantiti
surviv
degrad
mucos
surfac
gastro
intestin
tract
therefor
develop
new
vector
abl
effici
deliv
molecul
target
tissu
repres
technolog
challeng
today
suffici
data
avail
support
fact
lactic
acid
bacteria
lab
notabl
lactococci
lactobacilli
excel
candid
deliveri
vector
therapeut
protein
develop
novel
prevent
therapeut
strategi
human
lab
nonpathogen
gramposit
bacteria
extraordinari
safeti
profil
sinc
wide
consum
centuri
human
ferment
food
therefor
constitut
attract
altern
attenu
pathogen
popular
live
vector
use
current
attenu
pathogen
bacteria
deriv
mycobacterium
salmonella
bordetella
spp
particularli
well
adapt
interact
mucos
surfac
normal
use
initi
infect
process
unfortun
bacteria
recov
pathogen
potenti
therefor
entir
safe
use
human
especi
children
immunosuppress
patient
sever
detail
review
vector
deliveri
strategi
base
lab
publish
within
last
five
year
three
particularli
exhaust
convinc
herein
summar
current
research
advanc
use
lactococci
lactobacilli
live
deliveri
vector
protein
health
interest
also
describ
use
lab
dnavaccinedeliveri
vehicl
deliv
dna
directli
antigenpres
cell
immun
system
immunogen
solubl
protein
administ
oral
intranas
gener
low
significantli
enhanc
either
coupl
protein
bacteri
carrier
genet
engin
bacteria
result
product
desir
antigen
previous
mention
foodgrad
commens
gramposit
bacteria
constitut
attract
altern
attenu
pathogen
bacteria
particular
model
lab
lactococcu
lacti
certain
speci
lactobacilli
possess
number
properti
make
attract
candid
develop
mucos
vaccin
moreov
mani
antigen
andor
cytokin
success
express
lab
mucos
administr
genet
engin
lab
shown
elicit
system
mucos
immun
see
addit
file
product
desir
antigen
lab
occur
three
differ
cellular
locat
intracellular
allow
protein
escap
harsh
extern
environment
condit
gastric
juic
stomach
oral
administr
recombin
strain
requir
cellular
lysi
protein
releas
deliveri
ii
extracellular
allow
releas
protein
extern
medium
result
direct
interact
environ
food
product
digest
tract
iii
cell
wallanchor
combin
advantag
two
locat
ie
interact
cell
wallanchor
protein
environ
addit
protect
proteolyt
degrad
context
sever
studi
compar
product
differ
antigen
lab
use
three
locat
evalu
subsequ
immunolog
impact
review
ref
even
comparison
local
difficult
due
amount
protein
depend
local
studi
demonstr
highest
immun
respons
usual
obtain
cellwal
anchor
antigen
expos
surfac
lab
therefor
recent
lab
vaccin
studi
select
surfac
exposur
antigen
interest
rather
intraor
extracellular
product
l
lacti
wide
use
lab
product
ferment
milk
product
consid
model
lab
mani
genet
tool
develop
particular
heterolog
protein
product
moreov
l
lacti
consid
good
candid
heterolog
protein
product
secret
rel
protein
one
detect
quantiti
addit
commonli
use
laboratori
l
lacti
strain
plasmidfre
produc
extracellular
proteas
howev
major
advantag
use
l
lacti
live
vector
mucos
deliveri
therapeut
protein
resid
extraordinari
safeti
profil
sinc
bacterium
catalogu
noninvas
nonpathogen
organ
gra
statu
final
capac
l
lacti
produc
mani
differ
protein
health
interest
clearli
demonstr
last
two
decad
see
addit
file
featur
explain
relev
studi
focus
use
lab
protein
dna
deliveri
vector
perform
l
lacti
current
sever
induc
constitut
express
signal
avail
l
lacti
studi
mainli
use
nisin
induc
promot
pnisa
major
element
nice
nisin
induc
control
express
system
nisin
bacteriocin
produc
l
lacti
contain
eleven
adjac
chromosom
gene
nisabtciprkfeg
encod
biosynthesi
immun
nisin
nisa
gene
encod
structur
nisin
gene
wherea
nisrk
encod
dualcompon
system
respons
induct
gene
within
cluster
gene
interest
clone
downstream
p
nisa
result
plasmid
introduc
l
lacti
strain
carri
nisrk
gene
chromosom
addit
subinhibitor
nisin
concentr
level
cultur
medium
induc
express
gene
interest
proport
dose
nisin
use
system
consid
effici
one
heterolog
express
l
lacti
thu
develop
effici
heterolog
protein
productionsecret
system
l
lacti
base
p
nisa
small
stabl
wellcharacter
protein
staphylococcu
aureu
nucleas
nuc
famili
three
express
vector
pcyt
psec
pcwa
develop
allow
protein
target
either
intracellular
secret
cell
wall
anchor
respect
also
construct
fourth
express
vector
call
psec
leiss
contain
synthet
propeptid
leisstcda
identifi
productionsecret
booster
vector
also
function
sever
lab
speci
includ
lactobacilli
streptococci
enterococci
bifidobacteria
success
use
produc
approxim
differ
heterolog
protein
l
lacti
date
see
addit
file
recent
also
develop
new
bile
saltsinduc
promot
current
test
vivo
experi
data
shown
concern
possibl
host
factor
affect
productionsecret
l
lacti
identifi
ybdd
inactiv
induc
overproduct
secret
protein
morello
et
al
unpublish
data
addit
secret
machineri
l
lacti
also
complement
b
subtili
secdf
induc
increas
product
secret
rate
within
panel
l
lacti
strain
also
three
mutant
one
inactiv
uniqu
extracellular
housekeep
proteas
htra
one
inactiv
major
intracellular
proteas
clpp
one
inactiv
htra
clp
strain
essenti
reach
control
stabl
product
highli
degrad
protein
wild
type
l
lacti
strain
current
number
studi
support
use
recombin
l
lacti
induc
mucos
system
immun
respons
desir
antigen
first
attempt
use
l
lacti
mucos
vaccin
perform
kill
recombin
lactococci
produc
cell
wallattach
form
streptococcu
mutan
protect
antigen
pac
mice
immun
oral
kill
l
lacti
recombin
strain
develop
pacspecif
serum
igg
mucos
iga
antibodi
result
demonstr
first
time
l
lacti
effici
present
antigen
immun
system
well
et
al
report
first
time
use
live
recombin
l
lacti
produc
tetanu
fragment
c
ttfc
protect
mice
via
subcutan
inject
lethal
challeng
tetanu
toxin
afterward
group
evalu
effect
immun
rout
oral
nasal
administr
live
recombin
lactococci
produc
ttfc
mice
oral
immun
mice
result
lower
serum
igg
mucos
iga
antibodi
respons
compar
nasal
immunis
wherea
protect
efficaci
ie
challeng
tetanu
toxin
similar
rout
mani
studi
conduct
analyz
express
viral
bacteri
eukaryot
heterolog
protein
l
lacti
see
addit
file
immunogen
result
recombin
strain
evalu
mous
model
case
promis
result
amongst
one
best
document
project
base
use
recombin
l
lacti
produc
human
papillomaviru
type
antigen
viral
protein
consid
major
candid
antigen
vaccin
hpvrelat
cervic
cancer
second
caus
cancer
death
women
intracellular
product
antigen
led
rapid
degrad
cytoplasm
l
lacti
even
produc
proteasefre
clpp
strain
contrast
secret
cell
wallanchor
form
rescu
proteolysi
produc
higher
level
l
lacti
antigenspecif
humor
product
antibodi
cellular
secret
cytokin
respons
observ
intranas
administr
recombin
lactococci
express
antigen
differ
level
cellular
locat
mice
respons
significantli
higher
mice
immun
l
lacti
express
cell
wallanchor
form
subsequ
protect
effect
mucos
coadminist
live
l
lacti
strain
express
cell
wallanchor
secret
form
treat
tumor
murin
model
evalu
challeng
lethal
level
tumor
cell
line
express
pretreat
mice
demonstr
complet
prevent
tumor
therapeut
immun
recombin
strain
ie
day
inject
induc
regress
palpabl
tumor
treat
mice
preclin
result
suggest
feasibl
mucos
vaccin
andor
immunotherapi
hpvrelat
cervic
cancer
use
genet
engin
lactococci
although
immunolog
studi
perform
l
lacti
produc
ttfc
antigen
report
support
use
recombin
lactococci
mucos
vaccin
continu
grow
approxim
peerreview
public
valid
potenti
date
see
addit
file
cow
milk
allergi
cma
complex
disord
common
allergi
young
infant
incid
rate
decreas
adulthood
cma
develop
earli
infanc
within
month
birth
affect
children
recov
acquir
toler
cow
milk
age
year
l
lacti
engin
produc
blg
one
major
allergen
found
cow
milk
result
llblg
recombin
blg
produc
predominantli
solubl
intracellular
mostli
denatur
form
mucos
administr
llblg
strain
induc
blg
specif
fecal
iga
although
allergenspecif
ige
iga
detect
mice
sera
similar
immun
respons
report
oral
administr
recombin
l
lacti
secret
tcell
determin
ige
epitop
blg
adelpati
et
al
demonstr
oral
administr
recombin
l
lacti
strain
produc
differ
amount
recombin
blg
partial
prevent
mice
sensit
oral
pretreat
strain
prevent
immun
respons
elicit
system
sensit
via
reduct
specif
ige
induct
allergenspecif
fecal
iga
antibodi
intens
immun
respons
induc
correl
amount
recombin
blg
produc
sinc
effect
strain
produc
highest
amount
blg
similar
oral
administr
intranas
deliveri
recombin
l
lacti
strain
induc
secret
blg
specif
antibodi
elicit
product
murin
splenocyt
blg
restimul
intranas
pretreat
mice
llblg
reduc
airway
eosinophilia
influx
secret
broncoalveolar
lavag
bal
intranas
allergen
challeng
studi
intranas
coadministr
recombin
llblg
elicit
protect
immunerespons
inhibit
allerg
respons
mice
without
affect
specif
blg
ige
secret
elsewher
also
show
intranas
administr
strain
decreas
allergi
symptom
asthma
model
induc
ovalbumin
effect
intranas
administr
llblg
strain
also
test
therapeut
protocol
oral
sensit
mice
intranas
administr
recombin
strain
reduc
product
influenc
specif
blg
ige
secret
intranas
challeng
mild
decreas
secret
bal
detect
leptin
kda
protein
encod
obes
ob
gene
adipocytederiv
pleiotrop
hormon
modul
larg
number
physiolog
function
includ
control
bodi
weight
regul
immun
system
human
leptin
play
crucial
role
regul
bodi
weight
demonstr
morbid
obes
patient
congenit
mutat
either
leptin
leptin
receptor
gene
bodi
fat
increas
leptin
inhibit
food
intak
stimul
energi
expenditur
control
bodi
weight
although
leptin
treatment
induc
remark
weightloss
patient
rare
congenit
leptin
defici
show
poor
effici
obes
patient
inde
clinic
trial
involv
subcutan
administr
recombin
leptin
obes
subject
indic
signific
reduct
bodi
weight
observ
serum
leptin
concentr
higher
normal
physiolog
level
poor
respons
attribut
part
insuffici
transport
leptin
across
blood
brain
barrier
obes
patient
sinc
intranas
deliveri
effici
rout
administr
drug
directli
brain
consid
intranas
leptin
administr
may
interest
strategi
bypass
blood
brain
barrier
leptin
resist
human
thu
aim
project
measur
effect
intranas
administr
recombin
l
lacti
strain
secret
biolog
activ
form
leptin
lllep
obob
mice
first
demonstr
secret
recombin
leptin
fulli
biolog
activ
hormon
show
capac
stimul
report
gene
cell
transfect
obrb
leptin
receptor
immunomodulatori
activ
lllep
strain
evalu
vivo
coexpress
l
lacti
strain
express
human
papillomaviru
protein
mice
immun
intranas
lllep
strain
adapt
immun
respons
significantli
higher
mice
immun
demonstr
adjuvant
leptin
analyz
effect
daili
intranas
administr
lllep
obob
mice
thu
observ
treatment
induc
signific
reduct
bodi
weight
gain
food
intak
result
demonstr
leptin
produc
secret
activ
form
l
lacti
lllep
strain
regul
vivo
antigenspecif
immun
respons
well
bodi
weight
food
consumpt
use
genet
modifi
lactobacilli
ie
lb
fermentum
lb
acidophilu
lb
casei
lb
plantarum
produc
heterolog
protein
develop
new
gener
mucos
vaccin
first
propos
decad
end
earli
sever
laboratori
success
util
recombin
strain
lb
casei
lb
plantarum
vehicl
deliveri
medic
relev
protein
mucos
surfac
strain
stimul
strong
local
immun
respons
approxim
peerreview
public
alreadi
publish
confirm
advantag
lactobacillu
genu
serv
live
mucos
vaccin
sinc
lactobacilli
persist
longer
digest
tract
strain
probiot
properti
ie
show
healthpromot
activ
human
anim
similar
l
lacti
sever
studi
analyz
express
varieti
viral
bacteri
eukaryot
origin
protein
lb
plantarum
lb
casei
conduct
see
addit
file
evalu
immunogen
antigen
produc
recombin
lb
plantarum
mous
model
promis
result
recent
develop
recombin
strain
lactobacillu
casei
capabl
produc
blg
immunomodulatori
potenc
intranas
oral
administr
recombin
lactobacilli
subsequ
sensit
mice
blg
investig
hazebrouck
et
al
analyz
influenc
administr
rout
immun
respons
elicit
recombin
blg
lb
casei
produc
strain
intranas
preadministr
blgproduc
lb
casei
enhanc
blgspecif
respons
influenc
blgspecif
ige
product
sensit
mice
unexpectedli
oral
preadministr
led
signific
inhibit
blgspecif
ige
product
whera
respons
stimul
sensit
mice
product
blgreactiv
splenocyt
similar
oral
intranas
rout
administr
howev
blgreactiv
splenocyt
mice
intranas
pretreat
greater
secret
level
cytokin
cytokin
detect
suggest
mix
cell
respons
wherea
product
cytokin
cytokin
enhanc
blgreactiv
splenocyt
mice
oral
pretreat
result
indic
mode
administr
recombin
lab
may
critic
immunomodulatori
properti
antioxid
protein
deliveri
lb
casei
colitisinduc
murin
model
inflammatori
bowel
diseas
ibd
constitut
group
disord
character
chronic
relaps
inflamm
gastrointestin
tract
git
two
common
form
ibd
crohn
diseas
ulcer
coliti
associ
influx
neutrophil
macrophag
result
consequ
product
inflammatori
mediat
proteas
cytokin
reactiv
oxygen
speci
ro
ro
includ
superoxid
radic
hydrogen
peroxid
h
hydroxyl
radic
demonstr
cytotox
mutagen
ie
caus
damag
cellular
lipid
protein
dna
detoxifi
ro
cell
evolv
protect
mechan
via
antioxid
enzym
superoxid
dismutas
sod
catalas
cat
degrad
h
respect
therebi
preveningt
format
thu
therapeut
use
antioxid
enzym
decreas
ro
amount
level
promis
strategi
prevent
andor
cure
ibd
sever
studi
shown
lab
lactobacilli
may
play
prevent
role
ibd
context
origin
demonstr
lb
casei
strain
attenu
moder
dextran
sodium
sulfat
dss
induc
coliti
mice
howev
use
recombin
lb
casei
strain
produc
manganes
cat
mncat
improv
protect
effect
inflamm
reduct
hand
recent
studi
success
report
use
either
recombin
lb
gasseri
lb
plantarum
strain
produc
deliv
situ
biolog
activ
manganes
sod
mnsod
treat
coliti
knockout
mous
model
sulphon
acid
tnb
induc
coliti
rat
clone
mnsod
lactococcu
lacti
lb
casei
evalu
potenti
increas
aforement
protect
effect
toward
ro
deliveri
mnsod
therefor
compar
effect
intragastr
administr
lb
casei
mnsod
alon
combin
lb
casei
mncat
murin
model
dss
induc
coliti
base
histolog
score
signific
reduct
caecal
colon
inflamm
observ
either
administr
lb
casei
mnsod
alon
coadministr
lb
casei
mncat
lb
casei
mnsod
howev
addit
improv
inflamm
reduct
administr
lb
casei
mncat
compar
administ
lb
casei
mnsod
alon
result
suggest
lb
casei
mnsod
may
antiinflammatori
effect
gut
inflamm
recent
demonstr
lb
casei
mnsod
mncat
abl
significantli
attenu
tnbsinduc
inflamm
damag
mice
shown
higher
surviv
rate
decreas
anim
weight
loss
lower
bacteri
transloc
liver
prevent
damag
larg
intestin
advantag
dna
vaccin
reli
abil
induc
cellular
humor
immun
respons
contrast
bacteriamedi
deliveri
protein
antigen
bacteriamedi
deliveri
dna
vaccin
lead
express
posttransl
modifi
antigen
host
cell
result
present
conform
restrict
epitop
immun
system
protein
deliveri
use
foodgrad
lactococci
lactobacilli
dna
deliveri
vehicl
promis
altern
attenu
pathogen
l
lacti
abl
modul
host
immun
respons
cdna
deliveri
recombin
blg
express
mainli
denatur
form
e
coli
l
lacti
wherea
product
eukaryot
cell
nativ
conform
l
lacti
strain
use
deliv
express
cassett
encod
blg
cdna
transcript
control
cmv
viral
promot
epitheli
cell
line
express
cassett
insert
l
lacti
replic
plasmid
product
secret
blg
observ
cell
incub
l
lacti
carri
express
plasmid
demonstr
non
invas
l
lacti
deliv
fulli
function
plasmid
epitheli
cell
interestingli
product
blg
observ
cell
coincub
purifi
plasmid
alon
mix
l
lacti
suggest
plasmid
requir
insid
bacterium
order
achiev
transfer
epitheli
cell
subsequ
blg
product
oral
administr
l
lacti
mice
carri
eukaryot
express
cassett
encod
blg
blg
cdna
protein
detect
small
intestin
hour
final
administr
blg
proteindna
detect
day
last
oral
administr
mice
develop
blg
specif
primari
immun
respons
character
weak
transitori
serum
respons
sensit
pretreat
mice
ige
concentr
decreas
respect
compar
sensit
naiv
mice
moreov
splenocyt
pretreat
mice
secret
blg
specif
reactiv
situ
product
elicit
specif
immun
respons
protect
mice
sensit
cow
milk
protein
knowledg
first
evid
function
genet
materi
transfer
foodgrad
transit
bacteria
host
demonstr
recombin
e
coli
invas
host
cell
limit
step
achiev
effici
dna
vaccin
deliveri
increas
lactococc
dna
vaccin
deliveri
effici
l
lacti
render
invas
express
inla
gene
listeria
monocytogen
encod
internalin
surfac
protein
mediat
invas
non
phagocyt
cell
l
monocytogen
express
l
lacti
inla
promot
intern
lactoccocci
human
epitheli
line
vitro
enterocyt
vivo
oral
administr
guinea
pig
addit
l
lacti
inla
deliv
function
plasmid
encod
gfp
cell
express
gfp
cocultur
strain
recombin
invas
l
lacti
strain
express
staphylococcu
aureu
fibronectin
bind
protein
encod
gene
also
show
heighten
abil
intern
mammalian
cell
compar
control
strain
consequ
recombin
invas
strain
effici
egfp
express
plasmid
deliveri
cell
result
higher
number
gfp
produc
cell
vivo
l
lacti
inla
abl
invad
guinea
pig
enterocyt
oral
administr
consid
consist
data
togeth
obtain
group
see
addit
file
reinforc
interest
use
lactococci
lactobacilli
strain
develop
novel
therapeut
protein
mucos
deliveri
vector
test
human
clinic
trial
therefor
biocontain
strategi
prevent
dissemin
environ
genet
modifi
lab
develop
use
human
mention
recent
review
strategi
follow
demonstr
l
lacti
strain
could
treat
coliti
mous
model
steidler
et
al
develop
first
biocontain
system
strain
order
allow
start
first
human
clinic
studi
use
recombin
strain
address
safeti
concern
use
human
chromosom
thymidyl
synthas
thya
gene
replac
gene
encod
gener
thymidin
auxotroph
phenotyp
absenc
thymidin
thymin
viabil
thya
strain
reduc
sever
order
magnitud
contain
valid
vivo
pig
phase
clinic
trial
conduct
thya
strain
human
patient
suffer
diseas
demonstr
contain
strategi
effect
follow
posit
result
phase
iia
trial
perform
press
releas
publish
end
reveal
three
primari
endpoint
studi
met
safeti
toler
ii
environment
contain
iii
assess
biomark
associ
strain
respect
secondari
endpoint
clinic
result
reveal
statist
signific
differ
mucos
heal
versu
placebo
view
result
author
pioneer
human
clinic
trial
team
involv
promis
field
consid
optim
aspect
lab
deliveri
strategi
improv
done
differ
level
natur
deliv
molecul
ii
lab
speci
lb
casei
exampl
seem
show
advantag
compar
l
lacti
iii
express
system
increas
quantiti
deliv
molecul
situ
effort
need
continu
futur
prophylact
therapeut
strategi
base
recombin
lactococci
lactobacilli
requir
clear
demonstr
efficaci
human
clinic
trial
lead
better
accept
addit
file
summari
therapeut
protein
express
lactococci
lactobacilli
valid
anim
studi
